693 The gp130/STAT3 Axis Is Modulated by Lipotoxic Stress and Activated in Humans With Nonalcoholic Fatty Liver Disease

Abstract

A S L D A b st ra ct s random-effects model; Q-statistic with p-value 50% for both estimates). SVR rates in HCV-6 patients were 79.1% (CI=73.2-84.0%) if treated for 48 weeks and 58.7% (CI=46.0-70.2%) if treated for 24 weeks. When compared to HCV-1 patients, those with HCV-6 treated for 48 weeks had higher SVR, OR 2.73 (1.69-4.41, p<0.001) (Figure 1). This difference was not statistically significant when comparing HCV-6 patients treated for only 24 weeks to HCV-1 patients, OR 1.80 (0.72-4.48, p=0.206). SVR in patients with early virologic response (EVR, undetectable HBV RNA PCR at week 12 of therapy) was 66% (CI=54.2-76.4%) for HCV-1 and 81.6% (CI=75.3-86.6%) for HCV-6 patients treated for 48 weeks. There was no statistically significant difference in SVR between HCV-6 patients treated for 48 weeks versus patients with HCV-1 if they all had EVR, OR 2.02 (CI=0.864.76, p=0.106). Conclusions: Patients with HCV-6 treated for 48 weeks had higher SVR than patients with HCV-1 (79.1% vs. 71.8%, OR=2.73, p<0.001); however, SVR for Asian HCV-1 appeared much higher than SVR to PEG IFN+RBV for HCV-1 in pivotal registration trials with mostly Western patients. In patients with EVR, there is no difference in SVR rates between HCV-1 and HCV-6 who were treated for 48 weeks.